Ou Jia (Emilie) Wang, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Joseph M Lam, MD, FRCPC, Department of Pediatrics, Department of Dermatology and Skin Sciences, University of British Columbia,
Vancouver, British Columbia, Canada.

Abstract
Pityriasis alba is a common, benign skin condition that primarily affects children and adolescents, characterized by hypopigmented patches and scaly plaques on the face and other areas of the body. It is likely a manifestation of post-inflammatory hypopigmentation from subtle or subclinical inflammation. Diagnosis is typically based on history and clinical presentation. Management involves the use of emollients and low-potency topical steroids to improve skin hydration, reduce inflammation, and alleviate symptoms such as pruritus. Pityriasis alba typically becomes less apparent as the patients age, but reassurance and symptomatic relief are critical components to managing the condition.
Key Words: Pityriasis alba, atopy, hypersensitivity, scaling, hypopigmentation, asymptomatic.

Introduction
Pityriasis alba (PA) is a common dermatological condition typically seen in children and adolescents. It can also be occasionally diagnosed in adults. It is often associated with a history of atopy, and in many cases, coexists with atopic dermatitis.^1,2 The Greek term “pityriasis” means bran, which manifests as fine scale present in the plaques, and “alba” refers to the paleness from hypopigmentation. Around a century ago, PA was recognized as a localized disorder distinct from and less noticeable than vitiligo. It is asymptomatic and does not require definitive treatment.³ It is generally a self-limiting condition, with symptoms resolving spontaneously over months to years. These pale areas on the skin are more noticeable in patients with darker skin, resulting in higher reported incidence in patients with darker skin types.